In Phase A, individuals will get different doses and schedules of oral ABBV-744 tablet to discover Harmless dosing regimen. More participants is going to be enrolled within the identified monotherapy dosign regimen. In Section B, members will acquire oral ruxolitinib and ABBV-744 will be presented as "increase-on" therapy. In Phase https://tommyz211lwg3.weblogco.com/profile